Browse > Article
http://dx.doi.org/10.7181/acfs.2021.00003

Scientific review of the aesthetic uses of botulinum toxin type A  

Park, Mee Young (Department of Neurology, Yeungnam University Medical Center)
Ahn, Ki Young (Dr. Ahn's Aesthetic and Plastic Surgical Clinic and Botulinum Center)
Publication Information
Archives of Craniofacial Surgery / v.22, no.1, 2021 , pp. 1-10 More about this Journal
Abstract
Botulinum toxin type A (BoNT-A), onabotulinumtoxinA (Botox) was approved by the United States Food and Drug Administration for temporary improvement of glabellar lines in patients 65 years and younger in 2002, and has also been used widely for aesthetic purposes such as hyperhidrosis, body shape contouring, and other noninvasive facial procedures. BoNT-A inhibits presynaptic exocytosis of acetylcholine (ACh)-containing vesicles into the neuromuscular junction at cholinergic nerve endings of the peripheral nervous system, thereby paralyzing skeletal muscles. ACh is the most broadly used neurotransmitter in the somatic nervous system, preganglionic and postganglionic fibers of parasympathetic nerves, and preganglionic fibers or postganglionic sudomotor nerves of sympathetic nerves. The scientific basis for using BoNT-A in various cosmetic procedures is that its function goes beyond the dual role of muscle paralysis and neuromodulation by inhibiting the secretion of ACh. Although the major target organs for aesthetic procedures are facial expression muscles, skeletal body muscles, salivary glands, and sweat glands, which are innervated by the somatic or autonomic nerves of the peripheral cholinergic nerve system, few studies have attempted to directly explain the anatomy of the areas targeted for injection by addressing the neural physiology and rationale for specific aesthetic applications of BoNT-A therapy. In this article, we classify the various cosmetic uses of BoNT-A according to the relevant component of the peripheral nervous system, and describe scientific theories regarding the anatomy and physiology of the cholinergic nervous system. We also review critical physiological factors and conditions influencing the efficacy of BoNT-A for the rational aesthetic use of BoNT-A. We hope that this comprehensive review helps promote management policies to support long-term, safe, successful practice. Furthermore, based on this, we look forward to developing and expanding new advanced indications for the aesthetic use of BoNT-A in the future.
Keywords
Acetylcholine; Botulinum toxin, type A; Cholinergic nervous system; Diffusion; Dilution; Esthetics; Motor endplate; Pharmacology;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Botox (OnabotulinumtoxinA) [package insert]. Irvine (Botox) [package insert]. Irvine: Allergan; 2011.
2 Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.   DOI
3 Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30: 804-14.   DOI
4 Wei J, Zhu X, Yang G, Shen J, Xie P, Zuo X, et al. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: a meta-analysis of randomized controlled trials. Brain Behav 2019;9:e01409.
5 Calvani F, Santini S, Bartoletti E, Alhadeff A. Personal technique of microinfiltration with botulin toxin: the SINB technique (superficial injection needling botulinum). Plast Surg (Oakv) 2019;27:156-61.   DOI
6 Carruthers A, Carruthers J. History of botulinum toxin for medical and aesthetic use. In: Cohen JL, Ozog DM, Porto DA, editors. Botulinum toxins: cosmetic and clinical applications. Hoboken: John Wiley & Sons Inc.; 2017. p. 1-12.
7 Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol 1949;109:10-24.   DOI
8 Lipham WJ. A brief history of the clinical applications of botulinum toxin. In: Lipham WJ, editor. Cosmetic and clinical applications of botulinum toxin. Thorofare: SLACK; 2004. p. 1-3.
9 Brooks VB. The action of botulinum toxin on motor-nerve filaments. J Physiol 1954;123:501-15.   DOI
10 Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87:1044-9.   DOI
11 Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum: a exotoxin. J Dermatol Surg Oncol 1992;18:17-21.   DOI
12 Ahn KY, Park MY, Park DH, Han DG. Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans. Plast Reconstr Surg 2000;105:778-84.   DOI
13 Kane M, Donofrio L, Ascher B, Hexsel D, Monheit G, Rzany B, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol 2010;9(1 Suppl):s7-22.
14 Ahmed NY, Knowles R, Dehorter N. New insights into cholinergic neuron diversity. Front Mol Neurosci 2019;12:204.   DOI
15 Sine SM. End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. Physiol Rev 2012;92:1189-234.   DOI
16 Pijning AE, Chiu J, Yeo RX, Wong JW, Hogg PJ. Identification of allosteric disulfides from labile bonds in X-ray structures. R Soc Open Sci 2018;5:171058.   DOI
17 Shone CC. Clostridium botulinum neurotoxins, their structures and modes of action. In: Watson DH, editor. Natural toxicants in foods. Chichester: Ellis Harwood Ltd; 1986. p. 11-57.
18 Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-7.   DOI
19 Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 1986;26:427-53.   DOI
20 Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 1986;103:535-44.   DOI
21 Pearce LB, First ER, MacCallum RD, Gupta A. Pharmacologic characterization of botulinum toxin for basic science and medicine. Toxicon 1997;35:1373-412.   DOI
22 Brin MF, Dressler D, Aoki KR. Pharmacology of botulinum toxin therapy. In: Brin MF, Comella C, Jankovic J, editors. Dystonia: etiology, clinical feature, and treatment. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 93-108.
23 Jung GS, Cho IK, Sung HM. Submandibular gland reduction using botulinum toxin type A for a smooth jawline. Plast Reconstr Surg Glob Open 2019;7:e2192.   DOI
24 Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 2003;29:477-83.   DOI
25 Park MY, Ahn KY. The comparison of long-term effect of botox(R) injection on lower face contouring after single injection and long-term repeated injections by standardized photograph analysis. J Korean Soc Plast Reconstr Surg 2009;36:654-9.
26 Bi M, Sun P, Li D, Dong Z, Chen Z. Intralesional injection of botulinum toxin type A compared with intralesional injection of corticosteroid for the treatment of hypertrophic scar and keloid: a systematic review and meta-analysis. Med Sci Monit 2019;25:2950-8.   DOI
27 Park MY, Porto DA, Ahn KY. Contouring of the lower face and the lower leg and calf. In: Cohen JL, Ozog DM, Porto DA, editors. Botulinum toxins: cosmetic and clinical applications. Hoboken: John Wiley & Sons Inc.; 2017. p. 177-90.
28 Lee JH, Lee KY, Kim JY, Son WH, Jeong JH, Gil Jeong Y, et al. Botulinum toxin injection-site selection for a smooth shoulder line: an anatomical study. Biomed Res Int 2017;2017:3092720.   DOI
29 Al-Fouzan AF, Mokeem LS, Al-Saqat RT, Alfalah MA, Alharbi MA, Al-Samary AE. Botulinum toxin for the treatment of Gummv smile. J Contemp Dent Pract 2017;18:474-8.   DOI
30 Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 1999;103:645-52.   DOI
31 Kandhari R, Kaur I, Sharma D. Mesococktails and mesoproducts in aesthetic dermatology. Dermatol Ther 2020;33:e14218.   DOI
32 Childers MK. Targeting the neuromuscular junction in skeletal muscles. Am J Phys Med Rehabil 2004;83(10 Suppl):S38-44.   DOI
33 Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord 2013;28:1775-83.   DOI
34 Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 2009;40:374-80.   DOI
35 Stone HF, Zhu Z, Thach TQ, Ruegg CL. Characterization of diffusion and duration of action of a new botulinum toxin type A formulation. Toxicon 2011;58:159-67.   DOI
36 Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34-8.   DOI
37 Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994;9: 31-9.   DOI
38 Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, Caleo M. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci 2011;31:15650-9.   DOI
39 Aoki KR. Botulinum toxin: a successful therapeutic protein. Curr Med Chem 2004;11:3085-92.   DOI
40 Francisco GE, Tan H, Green M. Do botulinum toxins have a role in the management of neuropathic pain? A focused review. Am J Phys Med Rehabil 2012;91:899-909.   DOI
41 Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a doubleblind, randomized trial. Neurology 2005;65:765-7.   DOI
42 Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000;43(2 Pt 1):249-59.   DOI
43 Kim SH, Lee SJ, Kim HJ, Lee JH, Jeong HS, Suh IS. Aging-related changes in the mid-face skin elasticity in East Asian women. Arch Craniofac Surg 2019;20:158-63.   DOI